1)Knight A:The role of levocabastine in the treatment of allergic rhinoconjunctivitis. Br J Clin Prat 48:139-143, 1994
2)Abelson MB, George MA, Garofalo C:Differential diagnosis of ocular allergic disease. Ann Allergy 70:95-109, 1993
3)Hingorani M, Lightman S:Therapeutic options in ocular allergic disease. Drugs 50:208-221, 1995
4)角谷千恵子・荻野 敏・池田浩巳・他:スギ花粉症におけるアウトカム研究(第4報).アレルギー 54:627-635,2005
5)Abelson MB, Greiner JV:Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Curr Med Res Opin 20:1953-1958, 2004
6)Sharif NA, Xu SX, Yanni JM:Olopatadine(AL-4943 A):ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther 12:401-407, 1996
7)Brockman H, Graff G, Spellman J et al:A comparison of the effects of olopatadine and ketotifen on model membranes. Acta Ophthalmol Scand Suppl 78:10-15, 2000
8)Yanni JM, Stephens DJ, Miller ST et al:The in vitro and in vivo ocular pharmacology of olopatadine(AL-4943 A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther 12:389-400, 1996
9)Yanni JM, Weimer LK, Sharif NA et al:Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 117:643-647, 1999